Physician profile
Gerald Silverboard
NPI 1902972227
$11,130.35
in general payments reported to CMS, 2019-2025
57 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $1,174 · 2021: $1,461 · 2022: $1,769 · 2023: $2,084 · 2024: $1,508 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,684.21 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $743.06 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $725.53 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lundbeck LLC | $603.36 | 2019-2025 | Vyepti |
| Amgen INC. | $497.15 | 2019-2023 | Aimovig |
| Pfizer INC. | $470.58 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $459.85 | 2019-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $455.37 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $361.67 | 2019-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $349.76 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $341.91 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $306.00 | 2022 | |
| Lilly USA, LLC | $300.59 | 2019-2024 | Amyvid, Emgality, Kisunla |
| Allergan, INC. | $287.55 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $286.57 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Silverboard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.